The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Local consolidation and systemic therapy combinations in EGFR-mutated lung cancer
Saumil Ghandi, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, explores the future of local consolidation therapy in the treatment of EGFR-mutated lung cancer. Data from the NorthStar study (NCT04479306) showed a 90% control rate for tumors where radiation was delivered in patients who received radiotherapy alongside osimertinib. When progression occurred, it was not seen at sites where local consolidation therapy had been given. In the future, combinations of local and systemic therapies could make this disease chronic. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
